Inquis Medical, a cutting-edge med-tech company in Menlo Park, CA, has raised $40 million in Series B funding to drive advancements in thrombectomy technology. With support from major investors, the company is set to enhance patient care in vascular health.
- Funding Overview: Raised $40 million in Series B funding, with lead investor Marshall Wace, and with participation from ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond.
- Company Snapshot: Founded in 2020 by Vahid Saadat and Mojgan Saadat, co-CEOs focused on vascular health innovation.
- Why It Matters: Aventus aims to bring safer and more precise clot removal, enhancing physician control and patient outcomes.
By bringing advanced technology to vascular treatments, they’re setting new standards for precision and patient outcomes in the field of medical devices.
